Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032380 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT03032380 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 300 participants.
The verdict
NCT03032380, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.
Interventions
- DRUG Cefiderocol
- DRUG Meropenem
- DRUG Linezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03032380
The ClinicalTrials.gov registry entry for NCT03032380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cefiderocol is the first listed.
NCT03032380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03032380 about?
NCT03032380 is a clinical study titled "Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens". The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-as...
What is the current status of trial NCT03032380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2017-10-24. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03032380?
The interventions under investigation include: Cefiderocol (DRUG), Meropenem (DRUG), Linezolid (DRUG).
Who is sponsoring clinical trial NCT03032380?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.